Zafrens Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zafrens Inc. - overview
Established
2022
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022, Zafrens Inc. operates as a biotechnology company that provides an experimental platform to study. In February 2025, Zafrens Inc. raised an undisclosed amount of series A funding from new investor imec.
xpand. Returning investors Prime Movers Lab, KOFA Healthcare Investments, and Global Brain also participated in the round. As of December 2023, the company is led by its CEO Kandaswamy (Swamy) Vijayan. Zafrens develops an experimental platform that facilitates experiments while maintaining single-cell CITE-seq precision.
The experiments are accomplished within the time and cost parameters equivalent to a conventional 96-well plate experiment. The platform is also able to generate insights and allows navigation across diverse therapeutic modalities. The company plans to use the February 2025 funding to increase its capabilities and form new alliances with pharmaceutical firms across the globe.
Current Investors
Global Brain, BlueYard Capital, FoundersX Ventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Molecular Science, Genetics & Gene Therapy
Website
www.zafrens.com/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Zafrens Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.